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The antitumor and immunomodulatory activity of broken-spore of Ganoderma lucidum poly-
saccharides (Gl -BSP) were investigated in vivo and in vitro. It was showed that Gl -BSP (50,
100, and 200 mg kg−1) exhibited antitumor effect against Sarcoma 180 (S180) in BALB/c
mice. The Gl -BSP was not cytotoxicity in S180 cells and PG cells (human lung carcinoma
cell) in vitro. However, serum from Gl -BSP-treated S180-bearing mice significantly inhibited
S180 and PG cells proliferation in vitro. Moreover, Gl -BSP promoted the splenic lymphocyte
proliferation induced by Con A or LPS, enhanced nature killer cell (NK cell) cytotoxic activity,
augmented the percentage of neutral red phagocytosis by macrophages, and increased
the percentage of the CD4+ or CD8+ subset in S180-bearing mice. The serum level of
IFN-γ, TNF-α, and nitric oxide was increased by Gl -BSP. Gl -BSP also showed immunomod-
ulatory activities in tumor-bearing mice. Furthermore, neutralization with anti-TNF-α and/or
anti-IFN-γ significantly diminished growth inhibition induced by Gl -BSP-treated serum of
S180-bearing mice in S180 or PG cells. These observations suggest that the antitumor
activity of Gl -BSP may be mainly related to the activation of the immune response of the
host organism by the stimulation of NK cells, T cells, and macrophages.
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INTRODUCTION
Ganoderma lucidum (Leyss. et Fr.) Karst. (G. lucidum) is widely
used in China and other oriental countries (Lin, 2001). G. lucidum
(Lingzhi or Reishi) has been reported to be effective in modu-
lating immune functions, inhibiting tumor growth (Sliva et al.,
2002; Susan et al., 2002; Lin and Zhang, 2004), preventing oxida-
tive damage (Kim et al., 1999; You and Lin, 2002), protecting liver,
and reducing serum glucose levels, along with no toxicity (Zhang
et al., 2002; Zhang and Lin, 2003).
Polysaccharides are one of active component of G. lucidum.
Antitumor effects of polysaccharides isolated from G. lucidum
were originally observed in sarcoma 180 bearing mice (Miyazaki
and Nishijima, 1981; Sone et al., 1985). Recently, the antitumor
effects of G. lucidum polysaccharides have been extensively investi-
gated and were mainly through immune-related mechanisms (Xia
et al., 1989; Sakagami et al., 1991; Wang et al., 1997, 2002; Hu and
Lin, 1999; Yan et al., 1999; Zhang and Lin, 1999; Hsu et al., 2002,
2003; Wasser, 2002; Lee et al., 2003).
Recently, the spores of G. lucidum have attracted much atten-
tion for their versatile biological activities (Yang et al., 1997; Liu,
1999; Zhu et al., 2000; Liu et al., 2002; Lu et al., 2004). Bao et al.
(2000, 2001a,b) has isolated several polysaccharides from broken
or non-broken spores of G. lucidum, and proved these polysac-
charides have immunomodulatory activities. The release ability
of polysaccharides of broken spores has much greater than that
of non-broken spores (Bao and Fang, 2001). In this study, we
examined the antitumor activity of broken spore polysaccharides
(Gl-BSP) extracted fromG. lucidum, and investigated the potential
antitumor mechanism of Gl-BSP.
MATERIALS AND METHODS
ANIMALS
Inbred male 6–8 weeks old (body weight 18–22 g) BALB/c (H-2
d) mice (Grade II, Certificate No scxk11-00-0004) were purchased
from the Department of Experimental Animals, Health Science
Center, Peking University, Beijing, China. All procedures were in
accordance to the Institute Ethical Committee for Experimental
Use of Animals.
CELL LINES
Murine Sarcoma 180 cell lines (S180) were obtained from Bei-
jing Tumor Institute. Human lung carcinoma cell lines (PG)
and YAC-1 cell lines were provided by Department of Pathol-
ogy and Immunology, Peking University Health Center. The cells
were maintained in RMPI-1640 supplemented with 10% fetal calf
serum (FCS) in a humidified environment at 37˚C and 5% CO2,
and cultures were passaged every 2 or 3 days.
DRUGS
Gl-BSP was kindly provided by Fuzhou Institute of Green Val-
ley Bio-Pharm Technology. It was a sandy beige water sol-
uble powder and was isolated from boiling water extract of
the broken-spore of G. lucidum (Leyss. et Fr.) Karst. (Gl),
followed by ethanol precipitation, dialysis, and protein deple-
tion using Sevag method. The purity of the Gl-BSP was 97%,
which was analyzed by high-performance liquid chromatogra-
phy (HPLC). The component sugars and molecular-weight dis-
tributions of the glycopeptides were determined by gel perme-
ation chromatography (GPC) and HPLC. The structures of the
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glycopeptides were detected by IR, 1H NMR, and 13C NMR.
Gl-BSP had a molecular weight of 512,500 with a ratio of
polysaccharides to peptides of 94.8:5.2%. The polysaccharides
consisted of d-rhamnose, d-xylose, d-fructose, d-galactose, and
d-glucose with a molar ratio of 0.549:3.614:3.167:0.556:6.89
linked together by β-glycosidic linkages. The peptides con-
tained the following 16 amino acids: Asp, Thr, Ser, Glu, Gly,
Ala, Cys, Val, Met, Ile, Leu, Phe, Lys, His, Arg, and Pro. Gl-
BSP was dissolved in physiological saline for in vivo experi-
ments or in serum-free RPMI-1640 (Gibco Laboratories, Grand
Island, NY, USA) for in vitro experiments, filtered through a
0.22µm filter and stored at 4˚C for future use. Endotoxins con-
centration in Gl-BSP samples were assayed under endotoxin-
free experimental conditions by using a limulus amebocytes
lysate chromogenic assay kit (Beijing BXGK Technology Devel-
opment Co., Ltd., Beijing, China) according to the manufac-
ture’s instruction. The quantity of endotoxin in Gl-BSP was less
than 0.01 EU mg−1, indicating that endotoxin contamination in
Gl-BSP was negligible.
ANTITUMOR EXPERIMENT IN TUMOR-BEARING MICE
Murine Sarcoma 180 cell lines were injected into peritoneal cavity
of mouse, proliferated there to produce ascites, and were main-
tained by weekly transplantation of the tumor cells from ascites
into another peritoneal cavity of mouse. S180 were taken out from
the ascites, adjusted concentration as 1× 107 cells ml−1 with phys-
iological saline, and then injected in 0.2 ml (2× 106 cells) into the
axillary fossa of a mice right foreleg to prepare tumor-bearing
mice. The 50 mice were divided into five groups randomly (10
mice in each group) 24 h after the tumor inoculation and treated
for 14 consecutive days with (1) low-dose Gl-BSP (50 mg kg−1)
once daily by gavage, (2) intermediate-doseGl-BSP (100 mg kg−1)
once daily by gavage, (3) high-dose Gl-BSP (200 mg kg−1) once
daily by gavage, (4) cyclophosphamide (CY, an antitumor agent,
30 mg kg−1) once every other day by intraperitoneal injection as
positive controls, and (5) sterile physiological saline (10 ml kg−1)
once daily by gavage as negative controls (model group), and the
sixth group of normal mice administrated sterile physiological
saline intragastrically once daily (10 ml kg−1) served as normal
control.
After completion of treatment on the 14th day, the mice
were killed and the tumors were removed and weighted. At
the same time, blood samples were collected from the orbital
vein and the serum was sterilized by filtration and preserved
at−70˚C.
PG CELLS AND S180 CELLS PROLIFERATION ASSAY
PG or S180 cells were maintained in RMPI-1640 supplemented
with 10% FCS. A cell suspension (2× 107 cell per liter) was planted
onto 96-well plates (0.1 ml per well), and incubated at 37ºC, 5%
CO2 for 24 h. The media was replaced with 0.1 ml of RPMI-
1640 supplemented with 5% FCS and Gl-BSP 0.1, 1, 10, 100, or
400 mg l−1. In another series, RPMI-1640 was supplemented with
5% Gl-BSP treated serum 50, 100, or 200 mg kg−1. After 48 h,
cells proliferation was estimated based on the cellular reduction
of tetrazolium salt MTT by a microplate reader (BIO-RAD, Model
550), using a test wavelength of 540 nm.
PREPARATION OF SPLEEN LYMPHOCYTES
Mice in all treated groups were killed and the spleens were asepti-
cally removed, chopped with two slides and filtered over a fine
nylon mesh to obtain single-cell suspensions. The cells were
washed and lymphocytes were separated from red blood cells
by Tris-HCl-buffered NH4Cl solution [mix 9 volumes of 0.83%
NH4Cl with 1 volume of Tris-HCl (2.06%, pH 7.65), adjust pH
7.2]. Cells were finally suspended in 10% FCS RPMI-1640 supple-
mented with benzylpenicillin 100 kU l−1, streptomycin 100 mg l−1
for further experiments.
DETERMINATION OF PROLIFERATION OF LYMPHOCYTES
Lymphocytes were planted into 96-well plates (2× 106 cells per
well) with or without ConA 1 mg l−1 or LPS 5 mg l−1, and incu-
bated at 37˚C, 5% CO2 for 72 h. Cell proliferation was estimated
based on the method of MTT.
SPLENIC NK CYTOTOXIC ACTIVITY ASSAY
The NK cell activity of spleen cells was determined by a 4 h
51Cr-release assay. Viable trypan blue-excluded lymphocytes were
counted. Cell survival rate was greater than 95%. Target cells
of YAC-1 were incubated for 1 h at 37˚C with Na51CrO4 and
were coated at a concentration of 1× 104 cells per well in
96-well U-bottomed culture plates after washing. Effectors and
targets were mixed at a ratio of 40:1 and incubated for 4 h
at 37˚C. Spontaneous release was determined from wells that
contained labeled target cells alone, and maximum 51Cr-release
was determined by addition of 1% Triton X-100 (Sigma). The
radioactivity of the supernatants was counted in γ-counter
(Beckman LS 6500). Specific cytotoxicity was calculated as: per-
centage specific release= 100× (cpm experimental release− cpm
spontaneous release)/(cpm maximum release− cpm spontaneous
release).
NEUTRAL RED PHAGOCYTOSIS ASSAY OF PERITONEAL MACROPHAGES
Macrophages were obtained from mice peritoneal exudates cells
(PECs). PECs were washed twice and resuspended in a RPMI-1640
medium containing 10% FCS. Peritoneal macrophages were fur-
ther isolated from the PECs by incubating the PECs (2× 105 cells
per well) in a 96-well plate at 37˚C, 5% CO2 for 4 h in a humid-
ified atmosphere to allow peritoneal macrophages to adhere. The
supernatants were discarded, and 0.075% Neutral red (NR) were
added and incubated for another 1 h. Cells were then washed
with PBS for three times to remove excess dye and incubated
with cell lysis buffer (1 M acetic acid: ethanol= 1:1) overnight.
The absorbance (OD) was measured at 540 nm in a microplate
reader (BIO-RAD, Model 550) and translated into phagocy-
tosis ratio for comparison: phagocytosis ratio= testOD/normal
controlOD× 100%.
MEASUREMENT OF SPLENIC T LYMPHOCYTE SUBPOPULATIONS
The cell concentration of lymphocytes was adjusted to
1× 07 ml−1. A volume of 20µl of FITC-labeled anti-mouse CD4
and 20µl of PE-labeled anti-mouse CD8 was added to 100µl
of the cell suspension. After incubation for 30 min at 4˚C, the
lymphocytes were rinsed three times with 1 ml of PBS, pH 7.4,
containing 0.5% BSA and 0.1% NaN3. CD4 and CD8 T-cell
Frontiers in Pharmacology | Ethnopharmacology July 2012 | Volume 3 | Article 135 | 2
Wang et al. Antitumor and immunomodulatory effect
subpopulations were analyzed by flow cytometry using a FACS
Calibur (Becton Dickinson).
ASSAY FOR CYTOKINES
Serum collected from tested mice were assayed for the level of IL-2,
TNF-α, and IFN-γ using commercially available kits from R&D
systems, with a solid-phase enzyme-linked immunoabsorbent
assay (ELISA) as described by the manufacturers.
PRODUCTION OF NITRITE ION
The amount of NO−2 present in fresh serum collected from tested
mice were assayed by Griess reagent, using NaNO2 as a standard.
Briefly, 50µl of serum was reacted with 50µl of Griess reagent
(1% sulfanilamide in 5% H3PO4 −0.1% naphthalene ethylendi-
amine dihydrochloride) for 10 min. The absorbance was then read
at 540 nm using a microplate reader.
STATISTICAL ANALYSIS
Statistical significance was determined by one-way ANOVA
employing the computer SPSS statistic package. P< 0.05 was
considered significant.
RESULTS
ANTITUMOR EFFECT OF GL-BSP ON SARCOMA 180 IN MICE
In in vivo experiment, mice were implanted with Sarcoma 180
and different dosages of Gl-BPS or physiological saline (model
group) were administrated intragastrically for 14 days. Compared
with the model group, Gl-BSP 100 and 200 mg kg−1 significantly
inhibited growth of Sarcoma 180 by 49.1 and 59.9%, respectively,
with no effect on body weight (Table 1).
EFFECT OF GL-BSP ON PROLIFERATION OF SARCOMA 180 AND PG
CELLS IN VITRO
Gl-BSP did not inhibit Sarcoma 180 and PG cell proliferation
in vitro when added directly to the cultured medium (Table 2); but
Gl-BSP (50, 100, and 200 mg kg−1)-treated serum of S180-bearing
mice markedly inhibited S180 or PG cell proliferation (Figure 1).
EFFECT OF GL-BSP ON SPLEEN LYMPHOCYTE PROLIFERATION
INDUCED BY CON A AND LPS IN S180-BEARING MICE
Compared with normal mice, proliferation of spleen lymphocyte
induced by Con A and LPS declined significantly in S180-bearing
mice administrated with physiological saline (model group), but
Gl-BSP administrated intragastrically promoted spleen lympho-
cytes proliferation induced by Con A and LPS in S180-bearing
mice (Table 3).
EFFECT OF GL-BSP ON SPLENIC NK CYTOTOXIC ACTIVITY IN
S180-BEARING MICE
Compared with normal mice, splenic NK cytotoxic activity in
model group was significantly lower, reduced from 35.6% down
to 8.3%, while Gl-BSP (50, 100, and 200 mg kg−1) administrated
intragastrically increased the splenic NK cytotoxic activity of
S180-bearing mice (Table 4).
EFFECT OF GL-BSP ON PHAGOCYTOSIS BY PERITONEAL
MACROPHAGES IN S180-BEARING MICE
Gl-BSP (50, 100, or 200 mg kg−1) could augment the percentage
of phagocytosis of NR by peritoneal macrophages in S180-bearing
mice (Table 5).
EFFECT OF GL-BSP ON T LYMPHOCYTE SUBPOPULATION IN
S180-BEARING MICE
Compared with normal mice, the percentage of the CD4+ or
CD8+ subset decreased markedly, while the CD4+/CD8+ ratio
increased significantly in the model group. The results indicated
that the number of CD8+ subset decreased more than that of
CD4+ subset. Compared with the model group, the percentage
of the CD4+ and CD8+ subset in S180-bearing mice treated with
Table 2 | Effect of Gl -BSP on proliferation of Sarcoma 180 cells and PG
cells in vitro (x¯ ± s).
Group Concentration (mg l−1) Inhibitory ratio (%)
Sarcoma 180 cells PG cells
(n=7) (n=5)
RMPI-1640 – 0.0 0.0





Table 1 | Antitumor effect of Gl -BSP on Sarcoma 180 in BALB/c mice (n=10, x¯ ± s).
Group Dose (mg kg−1×days) Body weight (g) Tumor weight (g) Inhibitory ratio (%)
Origin After
Model – 20.4±0.5 20.4±1.1 1.21±0.27 0
Gl -BSP 50 mg kg−1×14 20.9±0.9 20.4±0.9 0.84±0.42 30.7
100 mg kg−1×14 20.5±0.8 20.5±1.4 0.61±0.47* 49.1
200 mg kg−1×14 20.9±0.8 21.6±0.8** 0.48±0.39** 59.9
CY 30 mg kg−1×7 20.4±0.5 18.2±1.5 0.23±0.11*** 81.0
Mice were implanted with Sarcoma 180 and administrated with Gl-BPS (50, 100, or 200 mg kg−1) or physiological saline intragastrically for 14 days. At the end of
experiment, the tumor were removed and weighted. *P<0.05, **P<0.01, ***P<0.001 vs. model group.
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FIGURE 1 | Effect of Gl -BSP-treated serum on proliferation of S180 and
PG cells in vitro (n=9, x¯ ± s). Mice were implanted with Sarcoma 180
and Gl -BPS (50, 100, or 200 mg kg−1) or physiological saline were
administrated intragastrically for 14 days. At the end of experiment, blood
samples were collected from the orbital vein and the serum was sterilized
by filtration. A cell suspension (2× 107 cell per liter) was made with 5% FCS
RPMI-1640, planted onto 96-well culture plates (0.1 ml per well), and
incubated at 37ºC, 5% CO2 for 24 h. The media was replaced with 0.1 ml of
RPMI-1640 supplemented with 5% Gl -BSP treated serum 50, 100, or
200 mg kg−1. After 48 h, cells proliferation was estimated by MTT. Data are
the mean±SD of three separate experiments. **P< 0.01, ***P<0.001
vs. S180-bearing control serum (model group).
Table 3 | Effect of Gl -BSP on spleen lymphocyte proliferation induced
by Con A and LPS in S180-bearing mice (n=5, x¯ ± s).
Group Dose (mg kg−1×days) Proliferation ratio (%)
Con A (1 mg l−1) LPS (5 mg l−1)
Normal – 254.0±8.4 127.0±8.8
Model – 130.3±8.3### 108.8±7.6##
CY 30 mg kg−1×7 (i.p, q.o.d) 105.0±2.1*** 71.2±5.7***
Gl -BSP 50 mg kg−1×14 184.3±3.4*** 115.5±8.9
100 mg kg−1×14 230.5±10.2*** 116.8±0.5
200 mg kg−1×14 236.4±6.7*** 123.4±5.7*
S180-bearing mice were administrated intragastrically with Gl-BPS (50, 100, or
200 mg kg−1) or physiological saline respectively for 14 days. At the end of experi-
ment, single splenic lymphocytes were adjusted to a concentration of 1×106 cells
per well in 96-well culture plates with or without ConA 1 mg l−1 or LPS 5 mg l−1,
and incubated at 37ºC, 5% CO2 for 72 h. Cell proliferation was estimated based
on the method of MTT. ##P<0.01, ###P<0.001 model group vs. normal group;
*P<0.05, ***P<0.001 vs. model group.
Gl-BSP (50, 100, or 200 mg kg−1) was greatly augmented, and
the ratio of CD4+/CD8+ reduced nearly to that in normal mice
(Table 6).
EFFECT OF GL-BSP ON PRODUCTION OF SERUM CYTOKINES IN
S180-BEARING MICE
On the basis of the effect of Gl-BSP on splenic lymphocytes,
NK cells, and peritoneal macrophages, the production of serum
cytokines was detected. We found that IL-2, IFN-γ, and TNF-α in
serum were undetectable in normal mice. Only IFN-γ in serum
Table 4 | Effect of Gl -BSP on splenic NK cytotoxic activity in
S180-bearing mice (n=5, x¯ ± s).
Group Dose (mg kg−1×days) Cytotoxicity (%)
Normal – 35.6±2.3
Model – 8.3±1.7###
CY 30 mg kg−1×7 (i.p, q. o. d) 0.6±0.5***
Gl -BSP 50 mg kg−1×14 13.8±1.0**
100 mg kg−1×14 21.4±2.9***
200 mg kg−1×14 30.3±1.1***
S180-bearing mice were administrated intragastrically with Gl-BPS (50, 100, or
200 mg kg−1) or physiological saline for 14 days, and the splenic NK cytotoxic activ-
ity of mice was examined in a 4-h 51Cr assay. Target cell: YAC-1. Effector: target
cell=40:1; ###P<0.001 model group vs. normal group; **P<0.01, ***P<0.001
vs. model group.
Table 5 | Effect of Gl -BSP on phagocytosis by peritoneal macrophages
in S180-bearing mice (n=5, x¯ ± s).
Group Dose (mg kg−1×days) Phagocytosis ratio (%)
Normal – 100.1±11.0
Model – 48.2±5.0###
Gl -BSP 50 mg kg−1×14 75.0±4.0**
100 mg kg−1×14 134.1±7.8***
200 mg kg−1×14 141.6±27.8***
S180-bearing mice were administrated intragastrically with Gl-BPS (50, 100, or
200 mg kg−1) or physiological saline respectively for 14 days. At the end of experi-
ment, the activity of peritoneal macrophages was measured by NR phagocytosis
assay. ###P<0.001 model group vs. normal group; **P< 0.01, ***P<0.001 vs.
model group.
was detectable in S180-bearing mice. The serum levels of IL-2,
IFN-γ, and TNF-α were markedly increased in S180-bearing mice
administrated with Gl-BSP (200 mg kg−1), compared with that in
S180-bearing control mice administrated with physiological saline
(Table 7).
ANTIBODY NEUTRALIZATION
To determine whether the growth inhibition in Sarcoma 180 cells
or PG cells induced by Gl-BSP 200 mg kg−1-treated serum was
related to the cytokines released from immune system activated
by Gl-BSP in S180-bearing tumor mice. Serums collected from
mice in all groups were preincubated with one or two cytokine-
neutralizing antibodies before addition to cell cultures. Neutral-
ization with anti-TNF-α apparently diminished S180 or PG cell
lines growth inhibition induced by Gl-BSP 200 mg kg−1-treated
serum, and a similar result was obtained by use of anti-IFN-
γ. Blocking effect was noted in the combination of anti-TNF-α
and anti-IFN-γ, which reduced the inhibition rate from 55.6
or 45.1% (before neutralization in S180 or PG cell lines) down
to 11 or 15.8%, respectively. However, the cytokine antibodies
used above did not completely block growth inhibition induced
by the Gl-BSP 200 mg kg−1-treated serum of S180-bearing mice
(Table 8).
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Table 6 | Effect of Gl-BSP onT lymphocyte subpopulation in S180-bearing mice (n=3, x¯ ± s).
Group Dose (mg kg−1×days) CD4+ (%) CD8+ (%) CD4+/CD8+
Normal – 33.67±0.94 18.14±1.46 1.86±0.11
Model – 20.98±0.26### 9.46±0.48### 2.22±0.12###
Gl -BSP 50 mg kg−1×14 22.73±0.31** 11.27±0.55** 2.02±0.09*
100 mg kg−1×14 22.99±0.92** 11.95±0.64*** 1.93±0.03**
200 mg kg−1×14 23.81±1.08*** 12.14±0.05*** 1.96±0.10**
S180-bearing mice were administrated intragastrically with Gl-BPS (50, 100, or 200 mg kg−1) or physiological saline respectively for 14 days; single splenic lymphocytes
were labeled with anti-mouse CD4-FITC and anti-mouse CD8-PE. The CD4 and CD8 T-cell subpopulations were analyzed by flow cytometry using a FACS Calibur.
###P<0.001 model group vs. normal group; *P<0.05, **P<0.01, ***P<0.001 vs. model group.
Table 7 | Effect of Gl -BSP on Production of Serum Cytokines and NO in S180-bearing mice (n=10, x¯ ± s).
Group IL-2 (pg ml−1) IFN-γ (pg ml−1) TNF-α (pg ml−1) NO2− (µM)
Normal control – UD UD UD 6.78±4.94
S180-bearing control – UD 11.73±3.53 UD 4.82±3.74
Gl -BSP 50 mg kg−1 UD 13.24±3.48 UD 12.97±2.45
100 mg kg−1 UD 20.13±2.93** 20.62±16.8 17.32±5.30**
200 mg kg−1 3.4±2.46*** 67.42±5.47*** 72.58±33.40*** 35.63±10.0***
S180-bearing mice were administrated intragastrically with Gl-BPS (50, 100, 200 mg kg−1) or physiological saline respectively for 14 days. At the end of experiment,
the serum was collected and the production of serum cytokines was detected by ELISA. Serum NO level was measured by Griess reagent. **P<0.01, ***P<0.001
vs. S180-bearing control; UD: undetected.
EFFECT OF GL-BSP-TREATED SERUMWITH OR WITHOUT HEAT
INACTIVATION ON PROLIFERATION OF S180 CELLS IN VITRO
We found that the Gl-BSP-treated serum of S180-bearing mice
had the different effects on Sarcoma 180 cell proliferation in vitro.
AfterGl-BSP 200 mg kg−1-treated serum underwent heat-inactive
at 56˚C for 30 min, the inhibition rate reduced from 57.1% down to
10.9%; while Gl-BSP 50 mg kg−1 and 100 mg kg−1-treated serum
with pretreatment at 56˚C for 30 min did not show significantly
effect on the proliferation of Sarcoma 180 cells in vitro (Figure 2).
DISCUSSION
In the present study, we investigated the antitumor activity of the
polysaccharides isolated from broken-spore of G. lucidum, Gl-
BSP. The spore of G. lucidum has a especially tough wall. Recently
some researchers indicated that broken spores have more activities
than non-broken spores (Zhu et al., 2000; Sliva et al., 2003; Wang
et al., 2005). In our research, we also compared the antitumor
and immunomodulatory effects of non-broken spore polysaccha-
rides (Gl-SP) and Gl-BSP extracted from G. lucidum. We found
that both Gl-SP and Gl-BSP could inhibit the tumor growth and
improve the immune function in tumor-bearing mice in vivo, but
Gl-BSP showed much higher bioactivities than Gl-SP (data not
showed).
β-Glucans are one of the most abundant forms of polysac-
charides found inside the cell wall of bacteria and fungus. All
β-glucans are glucose polymers linked together by a 1→ 3 lin-
ear β-glycosidic chain core and they differ from each other by
their length and branching structures. Fungal β-glucan is β-d-
glucose linked to one another by 1→ 3 glycosidic chain with 1→ 6
glycosidic branches whereas bacterial β-glucans have 1→ 4 side
branches. Bacterial endotoxin such as lipopolysaccharide (LPS) is
a potent immune stimulator and exogenous pyrogen, which causes
fever, shock, and disseminated intravascular coagulation. Endo-
toxin contamination can lead to false positive results in immune
tests and toxicity (Chan et al., 2009; Gertsch et al., 2011). Hence,
we evaluated the quantity of endotoxin in Gl-BSP by limulus ame-
bocytes lysate assay, which was less than 0.01 EU mg−1. This data
indicated that endotoxin contamination in Gl-BSP used in this
study was negligible. It should be noted that Gl-BSP is a complex
consisted of polysaccharides and peptide, but endotoxin has no
peptide. It is therefore possible that peptide in Gl-BSP may be
involved in some of the bioactivity of Gl-BSP. Furthermore, there
was no evident of toxic or side effect observed in Gl-BSP treated
mice during our experiments.
Kuang et al. (2007) used G. lucidum broken-spore powder
combined with chemotherapy in the treatment of 28 patients of
malignant neoplastic diseases. The patients were orally treated
with 0.9 g of G. lucidum broken-spore at a time, three times
a day, for 6 weeks, combined with chemotherapy at the same
time. Qi et al. (1999) used G. lucidum spore powder combined
with chemotherapy in the treatment of 100 patients of malig-
nant tumor. The patients were treated with 1 g of G. lucidum
spore at a time, three times a day, for a month, combined with
chemotherapy at the same time. The above clinical trials demon-
strated that G. lucidum spore’s adjuvant efficacy in treating cancer
patients by strengthening the immunity and decreasing toxic side
effects caused by chemotherapy, compared with chemotherapy
alone.
Extraction ratio of polysaccharides from G. lucidum spore is
about 2.4% (Lin et al., 2003). A dose of G. lucidum polysaccharides
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about 0.07 g per day in human is equal to about 10 mg kg−1 per day
in mice, according to the equivalent conversion of dose between
species (Mizuno et al., 1995). G. lucidum is approved by Min-
istry of Health in China as a new drug resource. Thus, less than
100 mg kg−1 Gl-BSP may represent a real dose and further study
is needed to confirm this assumption.
The present results showed that Gl-BSP inhibited the growth
of implanted Sarcoma 180 markedly. On the basis of the preceding
in vivo results, we examined the direct in vitro effects of Gl-BSP or
serum from Gl-BSP treated mice in Sarcoma 180 and PG cell cul-
tures. We found that Gl-BSP could not inhibit their proliferation
in vitro indicating thatGl-BSP had no direct cytotoxicity on tumor
cells. In contrast, Gl-BSP (50, 100, or 200 mg kg−1)-treated serum
could significantly inhibit Sarcoma 180 cells and PG cells prolif-
eration. Our previous studies imply that Gl-BSP can potentiate
Table 8 | Effect of Gl -BSP-treated serum of S180-bearing mice
preincubated with cytokine-neutralizing antibodies on the
proliferation of S180 and PG cells (n=10, x¯ ± s).
Group Inhibitory ratio (%)
S180 PG
Gl -BSP 200 mg kg−1-treated serum
alone
55.6±1.7 45.1±2.4
Gl -BSP 200 mg kg−1-treated
serum+ anti-TNF-α
32.5±1.2*** 29.0±4.0***
Gl -BSP 200 mg kg−1-treated
serum+ anti-IFN-γ
45.0±2.4*** 34.1±3.0***
Gl -BSP 200 mg kg−1-treated
serum+ anti-TNF-α+ anti-IFN-γ
11.3±0.9*** 15.8±3.3***
Gl-BSP 200 mg kg−1-treated serum of S180-bearing mice preincubated with or
without various cytokine-neutralizing antibodies (anti-TNF-α, 150 ng ml−1, and/or
anti-IFN-γ, 150 ng ml−1) at 37˚C for 90 min before addition to S180 or PG cells
cultures. Data are the mean±SD of 3 separate experiments. ***P< 0.001 vs.
Gl-BSP 200 mg kg−1-treated serum.
immunomodulatory activity in vivo that contributes significantly
to its antitumor activity (Wang et al., 2005).
We investigated the effect of Gl-BSP on splenic lymphocyte,
spleen NK cell and peritoneal macrophage activities in S180-
bearing BALB/c mice in vivo. The results in vivo were con-
sistent with those in vitro. Gl-BSP promoted the spleen lym-
phocytes proliferation induced by Con A or LPS, enhanced
NK cytotoxic activity, augmented the percentage of phagocyto-
sis of NR by macrophages, and increased the percentage of the
CD4+ or CD8+ subset in S180-bearing BALB/c mice. Gl-BSP
showed immunomodulatory activities in improving the immuno-
repressive state of tumor-bearing mice. The mean serum con-
centration of TNF-α, IFN-γ and NO apparently increased in
Gl-BSP-treated groups. TNF-α and IFN-γ play important roles in
depressing tumor cell growth and inducing apoptosis of tumor
cells (Spanaus et al., 1998; Smyth and Johnstone, 2000; Shin
et al., 2001; Ruiz de Almodovar et al., 2004). They are poten-
tial endogenous products in mediating the effect of Gl-BSP on
the immune system in vivo. Anti-TNF-α apparently diminished
the growth inhibitory effect of serum from Gl-BSP 200 mg kg−1-
treated S180-bearing mice in S180 or PG cell lines. Similar results
were obtained using anti-IFN-γ. Greater neutralization effect was
noted in the combination of anti-TNF-α and anti-IFN-γ in reduc-
ing the inhibition rate of serum from Gl-BSP 200 mg kg−1-treated
S180-bearing mice (55.6% before neutralization to 11.3% in S180
cell lines and from 45.1% before neutralization to 15.8% in PG cell
lines respectively). However, the cytokine antibodies used above
did not completely block growth inhibition of serum from Gl-
BSP 200 mg kg−1-treated S180-bearing mice in S180 or PG cell
lines suggesting other bioactive products in the serum, such as NO
and complements may also play a role.
There may be other active ingredients in the serum from Gl-
BSP-treated mice, such as NO, activated complement C3 and
metabolized substance of Gl-BSP. NO has been identified as the
major effector molecule involved in the destruction of tumor cells
by activated macrophages (Stuehr and Nathan, 1989; Keller et al.,
1990). Also, NO has been recognized as an important messen-
ger in diverse pathophysiological functions, including neuronal
FIGURE 2 | Effect of Gl -BSP-treated serum with or without 30 min 56˚C heat pretreatment on proliferation of S180 cells in vitro (n=10, x¯ ± s).
*P<0.05, **P<0.01, ***P< 0.001 vs. normal control.
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transmission, vascular relaxation, immune modulation, and cyto-
toxicity against tumor cells (Lowenstein et al., 1994). NO being a
gaseous free radical, has a short half life and is rapidly metabolized
to nitrate (NO -3 ) and nitrite (NO
-
2 ). So it is difficult to measure
NO directly, nitrate or nitrite are measured normally as indices of
NO production (Coleman, 2001). We observed the mean serum
concentration of NO increased in Gl-BSP -treated groups, espe-
cially in Gl-BSP 200 mg kg−1-treated group. As a result, NO in
serum might be another inhibitory component in suppressing the
growth of Sarcoma 180 or PG cells in vitro. Considering the activ-
ity of cytokines and NO, serum derived from all tested mice did not
be heat-inactive at 56˚C for 30 min in the former experiments. We
compared the different effect on proliferation of S180 cells in vitro
between Gl-BSP-treated serum with and without pretreatment at
56˚C for 30 min. The result showed some activated substances lost
theirs activity afterGl-BSP-treated serum underwent heat-inactive
at 56˚C for 30 min.
Although effect of humoral immunity to tumor is not as impor-
tant as that of cellular immune responses against tumor, IgM
and IgG1 (IgG3) which might be in Gl-BSP-treated serum could
mediate cytolytic activity with the help of component C3. A poly-
saccharide isolated from spores of G. lucidum showed significant
effect in enhancing the serum component C3 level in mice but
had a small effect in increasing the production of antibodies
against sheep red blood cells in mice (Bao et al., 2001a). Fur-
ther investigation is necessary to determine whether or not the
effect of Gl-BSP on the complement system and humoral immune
responses may also contribute to the antitumor mechanism of
Gl-BSP.
In summary, we demonstrated thatGl-BSP inhibited the tumor
growth and restored the depressed immune response in tumor-
burdened mice to the normal or near normal level. The anti-
tumor activity of Gl-BSP may be related to the activation of
the immune response of the host organism by the stimulation
of NK cells, T cells, and macrophage-dependent immune system
responses. Our results provide a clue that Gl-BSP may be con-
sidered as an efficacious adjacent immunopotentiating therapy in
the treatment of tumor where immunosuppression occurs. Fur-
ther studies are required to elucidate and confirm the effectiveness
of restoring the immune response by GL-BSP in the treatment of
tumor.
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